The expressions of estrogen receptor (ER) and cell surface receptor, Tyrosine Kinase Human Epidermal Growth Factor Receptor 2 (HER 2), have emerged as the most important molecular biomarkers determining the breast cancer prognosis. In this study, interactions between ER and HER2 were assessed to determine if they modulate tumor characteristics. Materials and Methods: Tissue samples from 120 patients with early stage breast cancer receiving adjuvant chemotherapy were reviewed to evaluate ER and HER2 status quantified by immunohistochemistry and fluorescence in situ hybridization, and the correlation of ER and HER2 with patient characteristics and tumor pathology was studied. Results: A total of 37(30.8%) and 80(66.6%) out of 120 samples were HER2 (3+ by immunohistochemistry or positive by fluorescent in situ hybridization) and ER positive (by immunohistochemistry), respectively. ER-negative tumors were significantly more likely to be HER-2 positive than were ER-positive tumors (21.25%; odds ratio, 0.270; 95% CI, 0.119 to 0.612; P=0.002). ER positivity was associated with <2 cm tumor size and higher histological grade (P=0.007 and 0.019, respectively). No significant correlation was seen between the coexpression of HER2 and ER and tumor characteristics. Conclusion: HER2 positive tumors were less common compared to ER positive tumors in early stage breast cancer Iranian patients. Also, higher histological grade among ER negative tumors showed higher aggressiveness of the tumor. Future studies are needed to evaluate the effect of receptor status on prognosis.
INTRODUCTION
Breast cancer is among the most common cancers affecting females worldwide (1) (2) (3) . According to a report by the Iranian Ministry of Health and Medical Education in Iran, breast cancer ranks first among the malignancies affecting females (4) . Some areas have a higher incidence of breast cancer such as East Africa (5) and the Middle East (including Iran) (6) . In Iran, the incidence of breast malignancies is increasing. Patients are affected at a younger age and mostly detected at advanced stages (7, 8) .
In breast cancer, determining the expression status of ER and cell surface receptor tyrosine kinas human epidermal growth factor receptor (HER2/neu or c-erb-B2) plays a critical role in choosing appropriate therapy (9) .
Estrogens potentially have mitogenic activity in normal
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Tanaffos 2014; 13 (1) : [26] [27] [28] [29] [30] [31] [32] [33] [34] and cancerous breast tissues (10) . Several studies have demonstrated this role in proliferation and progression of breast tumors by generating multiple growth-promoting signals (11) (12) (13) . Evidence suggests that ER located on or near the cell membrane can activate HER2 (14) .
Proliferation of breast tumoral cells and cell migration (15, 16) occur due to HER2 gene amplification and the relationships between HER2 and lymph node involvement, tumor size and grade have been documented (17) . It seems that HER2 over-expression or amplification in tumor cells is associated with a poorer outcome (18) .
The crosstalk between the ER and HER2 and the roll of HER2 in ER adjustment and balancing have been well known (19, 20) . Some investigators suggest that HER2 activates multiple intracellular signaling pathways leading to ER regulation. In normal breast tissue, current activation causes estrogenic effect. In addition, ER actively contributes to this pathway by down-regulation (21) of HER2 expression and activation of intracellular pathways leading to increased HER2 activity. However, in breast cancer, when estrogen concentrations are low, activation of HER 2 may affect ER and increase tumor growth (22) .
It was hypothesized that ER may act as a mediator in regulation of HER2 function.
To the best of our knowledge, there are few studies regarding the relationship of ER with HER2 with respect to tumor characteristics in Iran. Thus, the results of this study can provide basic information on breast cancer in Iranian females, and may help predict patient prognosis. In post-treatment follow-ups, patients underwent physical examination at least once every 4 months for the first 3 years, and every 6 months thereafter. Yearly mammograms, bone scans, and chest X rays were performed if necessary. 
MATERIALS AND METHODS
Statistical analysis
For testing the differences in categorical variables between the two groups, the chi-square test or Fisher's exact test was used. The difference in quantitative variables between the two groups was compared using the Student's t-test or non-parametric Mann-Whitney test. Estimated probabilities of HER2 positivity by significant factors were obtained from the models. Sensitivity and specificity of these models were derived, along with the receiver operating characteristic (ROC) curves, to assess how good the models were at predicting HER-2 positivity. All analyses were performed using SPSS version 21.
RESULTS
Tumor Pathology
One-hundred twenty patients were studied. Basic demographics of patients and pathological characteristics are shown in Table 1 .
The mean age of menarche was 13.8 years. Malignancy was seen in the right breast in 47.6% of patients and the remaining had tumors in their left breast (no one had bilateral disease).
The median tumor size was 1 cm. Invasive ductal carcinoma was found to be the most frequent pathology.
Modified radical mastectomy (MRM) and lumpectomy were performed for 88 and 32 patients, respectively. All patients received chemotherapy, and radiotherapy was performed in 56.7% of patients.
Association of HER2 positivity with other prognostic parameters HER 2 over-expression was seen in 30.8 %( n=37) of the analyzed samples. All patients with over-expression of HER2 had invasive ductal carcinoma. The incidence of lymph node involvement was 51.1% among patients with known HER2 over-expression, vs. 43.2% in group without HER2 over-expression (P=0.237).
Association of ER expression with other prognostic parameters
A significant association was found between ER and tumor size (P=0.007). It means that large tumors were significantly more ER negative. Also, a significant correlation was seen between the histological grade and ER expression (P=0.019). However, given the ER status, no association was found between age, nuclear grade, lymph node involvement and menopausal status ( Table 2) .
Relationship between HER-2 Status and clinical and pathological variables
ER negative tumors were significantly more likely to be HER2 positive than were ER positive tumors (21.25%; odds ratio, 0.270; 95% CI, 0.119 to 0.612; P =0.002, Table 1 ). Thus,
we selected the stepwise model including only the ER without the insignificant variables. The ROC curve from the reduced model is shown in Figure 1 . 
Association of ER and HER2 with other prognostic parameters
The relation between pairs of assessed ER and HER2
showed no association between parameters' characteristics ( Table 3) . (Table 1) . Likewise, a significant association was found between ER and tumor size (Table 2) . Also, a significant correlation was seen between ER negative tumors and high histological grade. In early stage breast cancer patients, data suggests that HER 2 status has a strong correlation with hormone receptors, especially ER.
In different studies, HER2 amplification was found in 20-30% of breast malignancies (27, 28) ; but in some We also confirmed that over-expression of HER2 was infrequent in invasive lobular cancers. However, our sample size was not large enough to exclude these cases from HER2 screening.
In several studies, nearly 50% of patients with HER2 amplification were also ER positive which is similar to the results of the present current study (31) . Also, the data of our study were similar to those of other studies in that HER2 over expression in breast cancer was associated with ER-negative status (32, 33) . Amplification of HER2
oncogene is related to increased proliferation and cell migration (16, 17) .
Moreover, the expression ratio of HER2 and ER varies between different geographical regions. ER expression was seen in 66.6% of our patients, which was similar to a study by Bartlett et al, (20) and higher than the result of MoradiMarjaneh et al (30) . An insignificant correlation was found between younger age, larger size and higher nuclear and histological grade and ER negativity, which indicates worse prognosis. This result is similar to that of a report by
Walker et al (34) .
In relation to breast cancer biology, many parameters are known, but tumors expressing ER have a relatively favorable prognosis. Results of the current study showed that ER negative tumors had significantly higher histological grade than ER positive ones (Table 2) Finally, the crosstalk between HER2 and ER status may help adopt multi-targeted strategies in the hope of improving patient outcome.
